Strong demand rallies Reckitt
STRONG demand for Finish dishwasher tablets and Strepsils lozenges helped to send underlying profit up by 30 per cent to £819million at household goods giant Reckitt Benckiser.
However, concerns RB might lose its exclusive US licence for heroin-dependency treatment Suboxone, which is responsible for 15 per cent of earnings, overshadowed the results. Shares rose 5p to 2868p.
Chief executive Bart Becht said the company, which also makes Cillit Bang, is beating the market and proving resilient to the recession.